B-D-Galactose

B-D-Galactose

SCHEMBL17112445

OCC1OC(O)[C@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 3/20 0.58
LGALS1 P09382 2/20 0.58
LGALS9 O00182 1/20 0.58
LGALS8 O00214 1/20 0.58
CA12 O43570 3/20 0.45
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA9 Q16790 3/20 0.45
PYGB P11216 6/20 0.44
GAA P10253 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 2/20 0.42
TSHR P16473 2/20 0.42
LMNA P02545 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
B-D-Galactose SCHEMBL9880688 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL10050866 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL2441804 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL13220216 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL18649521 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL8527882 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL23758905 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL79549 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL21123450 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL9820102 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210230178-A1 TRIOXACARCIN ANALOGS AND DIMERS AS POTENT ANTICANCER AGENTS WILLIAM MARSH RICE UNIVERSITY (US) 2021-07-29 US disclosed
US-10781183-B2 Small molecule inducers of reactive oxygen species and inhibitors of mitochondrial activity THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-09-22 US disclosed
US-20190308942-A1 SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-10-10 US disclosed
EP-3122376-A1 METABOLICALLY-ACTIVATED DRUG CONJUGATES TO OVERCOME RESISTANCE IN CANCER THERAPY The Brigham and Women's Hospital, Inc. (US) 2017-02-01 EP disclosed
WO-2015149001-A1 METABOLICALLY-ACTIVATED DRUG CONJUGATES TO OVERCOME RESISTANCE IN CANCER THERAPY THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190308942-A1 SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY SQOR, MAVS, TFAM LGALS3 2588/4885LGALS1 3068/4885LGALS9 3365/4885
US-20210230178-A1 TRIOXACARCIN ANALOGS AND DIMERS AS POTENT ANTICANCER AGENTS ANXA5, HCCS, BAX LGALS3 2628/4885LGALS1 2491/4885LGALS9 1516/4885
US-10781183-B2 Small molecule inducers of reactive oxygen species and inhibitors of mitochondrial activity SQOR, MAVS, TFAM LGALS3 2588/4885LGALS1 3068/4885LGALS9 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.